RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 128 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.27 and the average weighting 1.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $252,465 | +8.8% | 33,002 | +6.2% | 0.00% | – |
Q2 2023 | $232,048 | +67.4% | 31,064 | +49.5% | 0.00% | – |
Q1 2023 | $138,596 | -2.0% | 20,779 | +10.9% | 0.00% | – |
Q4 2022 | $141,434 | +20.9% | 18,733 | +14.6% | 0.00% | – |
Q1 2022 | $117,000 | -56.7% | 16,347 | +9.3% | 0.00% | -100.0% |
Q4 2021 | $270,000 | – | 14,957 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CRV, LLC | 733,986 | $16,889,000 | 37.30% |
MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 1,388,889 | $31,958,000 | 5.87% |
Yong Rong (HK) Asset Management Ltd | 377,000 | $8,675,000 | 5.69% |
Samsara BioCapital, LLC | 752,939 | $17,325,000 | 2.72% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $34,728,000 | 2.04% |
Spouting Rock Asset Management, LLC | 52,851 | $1,216,000 | 0.61% |
PLATINUM INVESTMENT MANAGEMENT LTD | 661,703 | $15,226,000 | 0.43% |
Laurion Capital Management LP | 3,923,713 | $90,285,000 | 0.38% |
Casdin Capital, LLC | 548,156 | $12,613,000 | 0.31% |
Baillie Gifford | 22,061,374 | $507,632,000 | 0.27% |